Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Copelan, Edward  [Clear All Filters]
Journal Article
Kilari D, D'Souza A, Fraser R, Qayed M, Davila O, Agrawal V, Díaz MÁngel, Chhabra S, Cerny J, Copelan E, et al. Autologous Transplantation for Male Germ Cell Tumors: Improved Outcomes over 3 decades. Biol Blood Marrow Transplant. 2019.
Zinter MS, Logan BR, Fretham C, Sapru A, Abraham A, Aljurf MD, Arnold SD, Artz A, Auletta JJ, Chhabra S, et al. Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries. Biol Blood Marrow Transplant. 2019.
Hamadeh IS, Zhang Q, Steuerwald N, Hamilton A, Druhan LJ, McSwain M, Diez Y, Rusin S, Han Y, Symanowski J, et al. Effect of CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Intravenous Tacrolimus Exposure and Adverse Events in Adult Allogeneic Stem Cell Transplant Patients. Biol Blood Marrow Transplant. 2018.
Saunthararajah Y, Sekeres M, Advani A, Mahfouz R, Durkin L, Radivoyevitch T, Englehaupt R, Juersivich J, Cooper K, Husseinzadeh H, et al. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. J Clin Invest. 2015.
Koon A, He J, Patel J, Morse A, Boseman V, Hamilton A, Knight T, Shah N, Ragon B, Chojecki A, et al. Evaluation of pentamidine tolerability and efficacy between phenotypes. Pharmacogenomics. 2023.
Oran B, Ahn KWoo, Fretham C, Beitinjaneh A, Bashey A, Pawarode A, Wirk B, Scott BL, Savani BN, Bredeson C, et al. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improves Transplant Outcomes in Older MDS Patients. Transplant Cell Ther. 2021.
Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralt S, Nishihori T, Martino R, Passweg J, et al. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study: Superior DFS with MAC comp. Biol Blood Marrow Transplant. 2020.
Nazha A, Hu Z-H, Wang T, R Lindsley C, Abdel-Azim H, Aljurf M, Bacher U, Bashey A, Cahn J-Y, Cerny J, et al. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients. Biol Blood Marrow Transplant. 2020.
Patel JN, Robinson M, Morris SA, Jandrisevits E, Lopes KEboli, Hamilton A, Steuerwald N, Druhan LJ, Avalos B, Copelan E, et al. Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing. Pharmacogenomics J. 2023.
Patel JN, Arnall J, Jandrisevits E, Morse AL, Steuerwald N, Copelan E, Walsh D. Pharmacogenomics-guided supportive oncology: A tale of two trials. Contemp Clin Trials. 2021:106391.
Zhou Z, Nath R, Cerny J, Wang H-L, Zhang M-J, Abdel-Azim H, Agrawal V, Ahmed G, A Al-Homsi S, Aljurf M, et al. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020;4(13):3180-3190.
Zhao JC, Arnall JR, Martin AL, Atrash S, Bhutani M, Voorhees P, Avalos B, Copelan E, Ghosh N, Hamadani M, et al. A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem-cell Transplant. Biol Blood Marrow Transplant. 2019.
Gowin K, Ballen K, Ahn KWoo, Hu Z-H, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020;4(9):1965-1973.